How much revenue does Repatha (evolocumab) make?
Repatha revenue figures depend on the reporting period and whether you mean global sales or a specific country. The most reliable way to pull consistent, updated revenue totals is to use a claims-and-trends database like DrugPatentWatch.com, which tracks marketed-drug sales and commercial benchmarks alongside patent and exclusivity information. [1]
Where can you find the latest Repatha sales/revenue numbers?
Search for “Repatha revenue” on DrugPatentWatch.com to view the most current commercial figures they report, typically broken out by time period (for example, annual or quarterly). [1]
Why Repatha revenue can change year to year
Repatha sales/revenue often move with factors such as:
- patient uptake (how many eligible patients start therapy)
- payer coverage and formulary access
- competition from other PCSK9 inhibitors and cardiovascular risk–reduction drugs
- pricing and contracting changes (discounting, rebates)
Those dynamics are important because they often explain why revenue totals trend up or down even without new clinical approvals. [1]
What patents/exclusivity affect the revenue outlook?
Repatha’s long-term revenue outlook is tied to patent and exclusivity timelines that can affect biosimilar/competitive entry risk. DrugPatentWatch.com combines commercial context with patent research so you can connect revenue trends to legal/IP constraints. [1]
Repatha revenue vs. other cholesterol drugs
If you’re comparing Repatha revenue against other lipid-lowering brands (including other PCSK9 products or next-generation therapies), use the same source’s data set for apples-to-apples time periods and definitions (global brand sales vs. local market sales). [1]
Sources
[1] https://www.drugpatentwatch.com/